Global Age-related Macular Degeneration Market report projects significant growth, with the market expanding from USD 11 billion in 2022 to USD 20 billion by 2032, achieving a compound annual growth rate (CAGR) of 6.2%. This comprehensive study highlights the rising prevalence of age-related macular degeneration (AMD) among the elderly and advancements in anti-VEGF therapies. The report provides actionable insights for stakeholders aiming to capitalize on the growing need for innovative treatments in ophthalmology.

What Are the Key Market Insights?

The global age-related macular degeneration market is thriving due to the increasing elderly population and the rising incidence of AMD, a leading cause of vision loss in those over 60. AMD exists in two forms: dry AMD, which involves macula thinning, and wet AMD, characterized by abnormal blood vessel growth treatable with anti-VEGF injections. The market is propelled by reimbursement policies, with Medicare covering 80% of bevacizumab and ranibizumab costs in the U.S., and 70% of manufacturers focusing on novel drug pipelines. Challenges include high treatment costs, a shortage of skilled ophthalmologists, and risks associated with anti-VEGF injections. Innovations in gene therapy and sustained-release implants are addressing these issues. North America dominates due to advanced healthcare infrastructure, while Asia-Pacific is a growth hotspot driven by aging populations in Japan and China. The competitive landscape is dynamic, with companies investing in biologics and AI-driven diagnostics.

What Are the Key Statistics and Forecasts?

The report forecasts the AMD market to grow from USD 11 billion in 2022 to USD 20 billion by 2032, with a CAGR of 6.2%, outpacing the 5.7% CAGR from 2017 to 2021. Wet AMD treatments, particularly anti-VEGF injections, dominate due to their efficacy. The U.S. holds a significant share, supported by Medicare reimbursement policies. Asia-Pacific is projected to grow rapidly due to a rising elderly population, with Japan and China leading. The market creates an absolute dollar opportunity of USD 9 billion over the forecast period. These projections reflect the market’s alignment with aging demographics and healthcare advancements.

How Can Industries Benefit from the Report’s Findings?

The report’s insights are valuable across multiple industries. In healthcare, anti-VEGF therapies and diagnostic tools improve patient outcomes in hospitals and clinics. The pharmaceutical industry benefits from developing novel biologics and gene therapies for AMD, addressing unmet needs. Research institutions leverage the report for advancing AI-driven diagnostics and sustained-release implants. The medical device sector uses imaging technologies for early AMD detection. Businesses can use the report to innovate treatment delivery, target high-growth regions like Asia-Pacific, and align with reimbursement policies to enhance market access.

What Are the Details of the Report and Publisher?

The Global Age-related Macular Degeneration Market report is built on a rigorous methodology, combining primary research through interviews with industry experts and secondary analysis of market trends and company reports. This ensures accurate, actionable insights for strategic decision-making. The report covers market dynamics, competitive landscapes, and regional analyses across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Who Are the Key Players?

The AMD market is competitive, with leading companies driving innovation. Novartis leads with its anti-VEGF drug Lucentis (ranibizumab). Roche excels with Avastin (bevacizumab) and Susvimo, a sustained-release implant. Regeneron Pharmaceuticals dominates with Eylea (aflibercept). Bayer and Apellis Pharmaceuticals focus on novel therapies for dry AMD. Other notable players include Bausch + Lomb, Allergan, and Genentech, all investing in gene therapy and AI diagnostics to address unmet needs.

What Are the Recent Developments in the Market?

Recent advancements are shaping the AMD market. In 2023, Regeneron received FDA approval for a high-dose Eylea formulation, improving treatment intervals. Roche launched Susvimo in 2022, a refillable implant for wet AMD, reducing injection frequency. Apellis introduced a novel dry AMD therapy in 2024, targeting complement inhibitors. Innovations in AI-driven retinal imaging are enhancing early diagnosis. Government healthcare spending, particularly in the U.S. and EU, is supporting access to AMD treatments. These developments highlight the industry’s focus on patient-centric solutions and innovation.

Conclusion

The Global Age-related Macular Degeneration Market report offers a comprehensive guide for stakeholders navigating the ophthalmology landscape. With a projected market value of USD 20 billion by 2032 and a 6.2% CAGR, the market is driven by aging populations and anti-VEGF advancements. Its applications in healthcare, pharmaceuticals, and diagnostics position it for sustained growth. Businesses can leverage the report to innovate, target high-growth markets, and align with reimbursement trends.